Amplyx grabs $67M to fund a pivotal drive to the FDA with an anti-fungal aimed at a lethal threat
Amplyx Plarmaceuticals is prepping a move into a pivotal Phase II program for its anti-fungal drug with a sizable $67 million round in hand to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
